The Fetal Bovine Serum Market Size was valued at USD 0.95 billion in 2023 and is projected to grow from USD 1.01 Billion in 2023 to USD 1.63 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.14% during the forecast period (2024 - 2032). One of the key market driver accelerating the growth and demand of the fetal bovine serum is the significant rise in culture media consumption in emerging nations worldwide.
June 2024: Omeat just released a white paper that provides detailed information about the performance of Plenty, their ethical alternative to Fetal Bovine Serum (FBS). The white paper includes feedback from third-party users regarding the efficacy of Plenty across various cell types. Omeat's procedure strictly follows the most stringent animal welfare criteria and employs cows that have been carefully chosen to be devoid of zoonotic diseases. The cows are able to freely forage on a spacious pasture, which avoids the necessity for ecologically harmful feedlots. Specifically, it is enhanced by platelet lysate. Platelets are little cellular fragments that encapsulate regenerative growth factors. They are enlisted at the location of the damage and stimulated to generate a regenerative milieu for the purpose of healing injuries in different organisms. Plenty is rich in growth factors and cytokines, which play a crucial role in organ regeneration, cell development, and differentiation.
Research and the biopharmaceutical industry both use stem cells extensively. So, in comparison to other products, its market worth is the highest. Because cellular reprogramming for induced pluripotent stem cells works so well, it has become very popular. It is superior than others due to the variety of tissue sources that are available. Fetal bovine serum is necessary for tissue development; hence, the market for it is expected to grow due to its wide range of applications. Fetal bovine serum also offers advantages in serum cell culture, including the capacity to distinguish between stem cells, morphology, cell proliferation and expansion, and clonal effectiveness. Thus, this factor is driving the market CAGR for fetal bovine serum.
Furthermore, fetal bovine serum is frequently used as a growth supplement for the cell culture of eukaryotic and mammalian cells in laboratories because it contains low levels of antibodies and high numbers of growth factors, as well as a complex composition of protein components necessary for the growth of many cells. Because of this, the serum is frequently employed in research projects at academic institutions. Fetal bovine serum is becoming more frequently used as a growth medium as a result of expanding research and development efforts in areas like cell culture. In the projected years, it is anticipated that this growing need will cause the growth curve of fetal bovine serum to accelerate.
However, the demand for fetal bovine serum is rising at an unprecedented rate in tandem with the advancement of technology and the pace of research and development activities. The serum's numerous applications have prompted the biopharmaceutical sector to create treatments and medications based on animals. Animal hosts are used to create drugs and vaccines, which has a number of benefits including low cost and high production volume of the final product. Thus, it is anticipated that this aspect will accelerate fetal bovine serum market revenue globally.
The Fetal Bovine Serum Market segmentation, based on type, includes Charcoal Stripped, Exosome Depleted and Stem Cell. The stem cell segment held the majority share in 2022 in the Fetal Bovine Serum Market data. Due to the fact that stem cells have a variety of uses in both research studies and the biopharmaceutical business, their market value is higher than that of other product categories. The high demand for the product is a result of cellular reprogramming's effectiveness in producing induced pluripotent stem cells.
The Fetal Bovine Serum Market segmentation, based on application, includes Drug Discovery, Cell Culture Media and In-Vitro Fertilization. The cell culture media segment dominated the market growth for fetal bovine serum in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Due to its properties, such as the presence of essential growth factors, minerals, proteins, vitamins, and other factors, foetal bovine serum is projected to be used in cell culture at a higher rate due to this growth. This is because the serum is highly suitable for the in vitro growth of eukaryotic cells.
The Fetal Bovine Serum Market data, based on end-user, includes Pharmaceutical and Biotechnology. The pharmaceutical segment dominated the fetal bovine serum market revenue for fetal bovine serum in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. As the highest level of product quality is required, high quality and pure foetal bovine serum is typically used for biopharmaceutical development. For the pharmaceutical industry, many businesses, as RMBIO, offer different supplements or foetal bovine serum products, which help to lower the overall cost. Pharmaceutical-grade foetal bovine serum is made available by businesses like Serox for the creation of new drugs or vaccines because to the growing demand for these products.
Figure 1: Fetal Bovine Serum Market, by End-User, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights for fetal bovine serum into North America, Europe, Asia-Pacific and Rest of the World. North America fetal bovine serum market accounted for USD 0.4 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The creation of significant organisations in the market and their ongoing attempts to manufacture extremely effective serum for research activities are credited with driving regional expansion. Furthermore, there is a significant concentration of cattle breeding in the area, which contributes to the plentiful supply of fetal bovine serum, which is obtained from slaughtered cows in slaughterhouses.
Further, the major countries studied in the market report for fetal bovine serum are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: FETAL BOVINE SERUM MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe fetal bovine serum market accounts for the second-largest market share as a result of expanded research and development efforts. Both commercially and intellectually, fetal bovine serum has found use. The market for fetal bovine serum in Europe is expanding as a result of increasing government funding for R&D, funding availability, a sophisticated healthcare system, and increased consumer desire for better alternatives. Further, the UK fetal bovine serum market held the largest market share, and the Germany fetal bovine serum market was the fastest growing market in the region.
Asia Pacific fetal bovine serum Market is expected to grow at the fastest CAGR from 2022 to 2030. Growing government assistance, an increase in the number of pharmaceutical companies, and rising consumer demand for improved medications are the main market drivers. Demand and supply for fetal bovine serum are out of balance in Australia and New Zealand due to rising medical needs. Moreover, China fetal bovine serum market held the largest market share, and the India fetal bovine serum market was the fastest growing market in the region.
Fetal Bovine Serum Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the fetal bovine serum market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the fetal bovine serum industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global fetal bovine serum industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, fetal bovine serum industry has provided medicine with some of the most significant benefits. The fetal bovine serum market major player such as HiMedia Laboratories, Merck KgaA, Bovogen Biologicals Pty Ltd, Atlanta Biologicals Inc., TCS Biosciences Ltd, Tissue Culture Biologicals, Rocky Mountain Biologicals, GE Healthcare, Thermo Fisher Scientific, Bio-Techne, PAN-Biotech and Access Biologicals.
A provider of scientific equipment, reagents, and consumables as well as software services in the United States is Thermo Fisher Scientific Inc. Thermo Electron and Fisher Scientific merged in 2006 to establish Thermo Fisher, which has its headquarters in Waltham, Massachusetts. In April 2021, the definitive agreement between Thermo Fisher Scientific Inc. and PPD Inc. was made public. Thermo Fisher will pay USD 17.4 billion to acquire PPD.
The Merck Group, also known as Merck, is a multinational science and technology firm with its headquarters in Darmstadt with operations in 66 different countries. Almost 250 businesses make up the organisation, with Merck KGaA in Germany serving as its centerpiece. In March 2021, with a EUR 25 million investment, Merck KgAA has announced that it will develop a single-use assembly production unit at its Life Science Center in Molsheim, France.
Key Companies in the fetal bovine serum market includes
Fetal Bovine Serum Industry Developments
June 2024: Omeat just released a white paper that provides detailed information about the performance of Plenty, their ethical alternative to Fetal Bovine Serum (FBS). The white paper includes feedback from third-party users regarding the efficacy of Plenty across various cell types. Omeat's procedure strictly follows the most stringent animal welfare criteria and employs cows that have been carefully chosen to be devoid of zoonotic diseases. The cows are able to freely forage on a spacious pasture, which avoids the necessity for ecologically harmful feedlots. Specifically, it is enhanced by platelet lysate. Platelets are little cellular fragments that encapsulate regenerative growth factors. They are enlisted at the location of the damage and stimulated to generate a regenerative milieu for the purpose of healing injuries in different organisms. Plenty is rich in growth factors and cytokines, which play a crucial role in organ regeneration, cell development, and differentiation.
September 2020: In order to promote the development of the biotechnology sector, Cytiva announced the expansion of its manufacturing capacity and the hiring of considerable numbers of new staff. To boost its manufacturing capacity, the corporation has budgeted an investment of approximately USD 500 million over five years.
December 2019: Biological Industries was purchased by Sartorius, a German life science research and biopharmaceutical firm, for $53.67 million. Through this acquisition, Sartorius increased its offering of cell culture media and complemented its product line for customers in the majority of the biological industries' expanding market for sophisticated therapies.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.95 billion |
| Market Size 2024 | USD 1.01 billion |
| Market Size 2032 | USD 1.63 billion |
| Compound Annual Growth Rate (CAGR) | Â 6.14% (2024-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Product, Application, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | HiMedia Laboratories, Merck KgaA, Bovogen Biologicals Pty Ltd, Atlanta Biologicals Inc., TCS Biosciences Ltd, Tissue Culture Biologicals, Rocky Mountain Biologicals |
| Key Market Opportunities | Research funding, and growing awareness about the high-end fetal bovine serum among medical professionals |
| Key Market Dynamics | Increase In Demand From Traditional Users Of Serum Higher Efficiency Rate Than Normal Blood Serum |
Fetal Bovine Serum market Market Highlights:
Frequently Asked Questions (FAQ) :
The Fetal Bovine Serum Market size was valued at USD 0.95 Billion in 2023.
The Fetal Bovine Serum Market is projected to grow at a CAGR of 6.14% during the forecast period, 2024-2032.
North America had the largest share in the global market for fetal bovine serum.
The key players in the market for fetal bovine serum are HiMedia Laboratories, Merck KgaA, Bovogen Biologicals Pty Ltd, Atlanta Biologicals Inc., TCS Biosciences Ltd, Tissue Culture Biologicals, Rocky Mountain Biologicals.
The stem cell dominated the fetal bovine serum market in 2022.
The pharmaceutical had the largest share in the Fetal Bovine Serum Market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
